	US 11,702,482 B2
	Twin immune cell engager
Martin Preyer, Somerville, MA (US); Allison Colthart, Everett, MA (US); Pamela Weinstein, Cambridge, MA (US); Patrick Wiencek, Cambridge, MA (US); Emma Geiger, Cambridge, MA (US); and Werner Meier, Burlington, MA (US)
Assigned to Revitope Limited, Hertfordshire (GB)
Filed by Revitope Limited, Hertfordshire (GB)
Filed on Dec. 16, 2019, as Appl. No. 16/715,621.
Claims priority of provisional application 62/780,770, filed on Dec. 17, 2018.
Prior Publication US 2020/0190213 A1, Jun. 18, 2020
Int. Cl. C07K 16/32 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/32 (2013.01) [A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2319/035 (2013.01); C07K 2319/74 (2013.01)]

21 Claims

1. A kit or composition for treating cancer in a patient comprising:

a. a first component comprising a targeted immune cell binding agent comprising:

i. a first targeting moiety that binds a tumor antigen expressed by the cancer;

ii. a first immune cell binding domain capable of immune cell binding activity when the first immune cell binding domain is bound to a second immune cell binding domain, wherein the second immune cell binding domain is not part of the first component, and wherein the first immune cell binding domain is either a VH domain or VL domain; and

iii. a first complementary binding domain capable of binding to a complementary antigen when the first complementary binding domain is bound to a second complementary binding domain, wherein

(1) the second complementary binding domain is not part of the first component,

(2) when the first immune cell binding domain is a VH domain the first complementary binding domain is a VL domain,

(3) when the first immune cell binding domain is a VL domain, the first complementary binding domain is a VH domain, and

(4) wherein the first complementary binding domain is a binding partner for the first immune cell binding domain, such that the first immune cell binding domain does not bind to the second immune cell binding domain unless the first immune cell binding domain is not bound to the first complementary domain; and:

b. a second component comprising a targeted immune cell binding agent comprising:

i. a second targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a tumor microenvironment cell;

ii. a second immune cell binding domain capable of immune cell binding activity when the second immune cell binding domain is bound to the first immune cell binding domain, wherein the second immune cell binding domain is a VH if the first immune cell binding domain is a VL and wherein the second immune cell binding domain is a VL if the first immune cell binding domain is a VH; and

iii. a second complementary binding domain capable of binding to a complementary antigen when the second complementary binding domain is bound to the first complementary binding domain, wherein

(1) when the second immune cell binding domain is a VH domain the second complementary binding domain is a VL domain,

(2) when the second immune cell binding domain is a VL domain, the second complementary binding domain is a VH domain, and

(3) wherein the second complementary binding domain is a binding partner for the second immune cell binding domain, such that the second immune cell binding domain does not bind to the first immune cell binding domain unless the second immune cell binding domain is not bound to the second complementary domain.